Scholich, H., Murphy, M
Green JB, Bethel MA, Armstrong PW, et al
The low prices for the drugs, currently not available for obesity patients on Medicare and Medicaid, are the result of a deal between the White House and drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY)
During this period, they evaluate whether an every-other-week (EOW) schedule maintains results without triggering hunger, weight regain, fluctuation in blood glucose levels, or metabolic instability
Branded vs Compounded GLP-1 Options Many patients arrive familiar with brand names like Wegovy, Ozempic, Mounjaro, and Zepbound
However, as the science shows, these GLP-1 patches cant deliver on those promises